Addendum
Andexanet alfa (acute major bleeding) - Addendum to Commission A19-76
Report documents
-
Addendum
Andexanet alfa (acute major bleeding) - Addendum to Commission A19-76
Dossier assessment
Indication:
Adults treated with apixaban or rivaroxaban when reversal of anticoagulation is needed due to major bleeding
Result of dossier assessment:
Conclusion of dossier assessment A19-76 unchanged: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.
Project details
- Project no.
- A20-02
- Commission
- Commission awarded on 06.01.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed